Q3 revenue from collaboration agreements were $11.6M and $11.9M for the three and nine months ended September 30, 2025, respectively, as compared to nil and $53.5M for three and nine months ended September 30, 2024.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR
- Repare Therapeutics trading halted, news pending
- Repare Therapeutics’ Promising Study on Advanced Solid Tumors: A Closer Look
- Repare Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
- Repare Therapeutics Unveils Phase 1 LIONS Trial Data